Platelet‐activating factor: a mediator for clinicians
1995; Wiley; Volume: 238; Issue: 1 Linguagem: Inglês
10.1111/j.1365-2796.1995.tb00894.x
ISSN1365-2796
AutoresTadaatsu Imaizumi, Diana M. Stafforini, Yoshiji Yamada, Thomas M. McIntyre, Stephen M. Prescott, Guy A. Zimmerman,
Tópico(s)Heart Failure Treatment and Management
ResumoJournal of Internal MedicineVolume 238, Issue 1 p. 5-20 Free Access Platelet-activating factor: a mediator for clinicians TADA-ATSU IMAIZUMI, TADA-ATSU IMAIZUMI Nora Eccles Harrison Cardiovascular Research and Training Institute, the Eccles Program in Human Molecular Biology and Genetics, and the Departments of Internal Medicine and Biochemistry, University of Utah, Salt Lake City, Utah, USASearch for more papers by this authorDIANA M. STAFFORINI, DIANA M. STAFFORINI Nora Eccles Harrison Cardiovascular Research and Training Institute, the Eccles Program in Human Molecular Biology and Genetics, and the Departments of Internal Medicine and Biochemistry, University of Utah, Salt Lake City, Utah, USASearch for more papers by this authorYOSHIJI YAMADA, YOSHIJI YAMADA Nora Eccles Harrison Cardiovascular Research and Training Institute, the Eccles Program in Human Molecular Biology and Genetics, and the Departments of Internal Medicine and Biochemistry, University of Utah, Salt Lake City, Utah, USASearch for more papers by this authorTHOMAS M. MCINTYRE, THOMAS M. MCINTYRE Nora Eccles Harrison Cardiovascular Research and Training Institute, the Eccles Program in Human Molecular Biology and Genetics, and the Departments of Internal Medicine and Biochemistry, University of Utah, Salt Lake City, Utah, USASearch for more papers by this authorSTEPHEN M. PRESCOTT, STEPHEN M. PRESCOTT Nora Eccles Harrison Cardiovascular Research and Training Institute, the Eccles Program in Human Molecular Biology and Genetics, and the Departments of Internal Medicine and Biochemistry, University of Utah, Salt Lake City, Utah, USASearch for more papers by this authorGUY A. ZIMMERMAN MD, Corresponding Author GUY A. ZIMMERMAN MD Nora Eccles Harrison Cardiovascular Research and Training Institute, the Eccles Program in Human Molecular Biology and Genetics, and the Departments of Internal Medicine and Biochemistry, University of Utah, Salt Lake City, Utah, USAUniversity of Utah Medical Center, CVRTI, Building 500, Salt Lake City, UT 84112, USASearch for more papers by this author TADA-ATSU IMAIZUMI, TADA-ATSU IMAIZUMI Nora Eccles Harrison Cardiovascular Research and Training Institute, the Eccles Program in Human Molecular Biology and Genetics, and the Departments of Internal Medicine and Biochemistry, University of Utah, Salt Lake City, Utah, USASearch for more papers by this authorDIANA M. STAFFORINI, DIANA M. STAFFORINI Nora Eccles Harrison Cardiovascular Research and Training Institute, the Eccles Program in Human Molecular Biology and Genetics, and the Departments of Internal Medicine and Biochemistry, University of Utah, Salt Lake City, Utah, USASearch for more papers by this authorYOSHIJI YAMADA, YOSHIJI YAMADA Nora Eccles Harrison Cardiovascular Research and Training Institute, the Eccles Program in Human Molecular Biology and Genetics, and the Departments of Internal Medicine and Biochemistry, University of Utah, Salt Lake City, Utah, USASearch for more papers by this authorTHOMAS M. MCINTYRE, THOMAS M. MCINTYRE Nora Eccles Harrison Cardiovascular Research and Training Institute, the Eccles Program in Human Molecular Biology and Genetics, and the Departments of Internal Medicine and Biochemistry, University of Utah, Salt Lake City, Utah, USASearch for more papers by this authorSTEPHEN M. PRESCOTT, STEPHEN M. PRESCOTT Nora Eccles Harrison Cardiovascular Research and Training Institute, the Eccles Program in Human Molecular Biology and Genetics, and the Departments of Internal Medicine and Biochemistry, University of Utah, Salt Lake City, Utah, USASearch for more papers by this authorGUY A. ZIMMERMAN MD, Corresponding Author GUY A. ZIMMERMAN MD Nora Eccles Harrison Cardiovascular Research and Training Institute, the Eccles Program in Human Molecular Biology and Genetics, and the Departments of Internal Medicine and Biochemistry, University of Utah, Salt Lake City, Utah, USAUniversity of Utah Medical Center, CVRTI, Building 500, Salt Lake City, UT 84112, USASearch for more papers by this author First published: July 1995 https://doi.org/10.1111/j.1365-2796.1995.tb00894.xCitations: 117AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Prescott SM, Zimmerman GA, McIntyre TM. Platelet-activating factor. J Biol Chem 1990; 265: 17381–4. 10.1016/S0021-9258(18)38167-5 CASPubMedWeb of Science®Google Scholar 2 Zimmerman GA, Prescott SM, McIntyre TM. Platelet-activating factor: a fluid phase and cell-associated mediator of inflammation. In: JI Gallin, IM Goldstein, R. Snyderman, eds. Inflammation: Basic Principles and Clinical Correlates, 2dn edn. New York: Raven Press, 1992: 149–76. Web of Science®Google Scholar 3 Hanahan DJ. Platelet-activating factor: a biologically active phosphoglyceride. Annu Rev Biochem 1986; 55: 483–509. 10.1146/annurev.bi.55.070186.002411 CASPubMedWeb of Science®Google Scholar 4 Whatley RE, Clay KL, Chilton FH, Triggiani M., Zimmerman GA, McIntyre TM and Prescott SM. Relative amounts of 1-0- alkyl- and 1-acyl-2-acetyl-sn-glycero-3-phosphocholine in stimulated endothelial cells. Prostaglandins 1992; 43: 21–9. 10.1016/0090-6980(92)90061-W CASPubMedWeb of Science®Google Scholar 5 Smiley PL, Stremler KE, Prescott SM, Zimmerman GA, McIntyre TM. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem 1991; 266: 11104–10. 10.1016/S0021-9258(18)99133-7 CASPubMedWeb of Science®Google Scholar 6 Snyder F. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am J Physiol 1990; 159: C697–708. Google Scholar 7 Venable MA, Zimmerman GA, McIntyre TM, Prescott SM. Platelet-activating factor: a phospholipid autacoid with diverse actions. J Lipid Res 1993; 34: 691–702. 10.1016/S0022-2275(20)39691-7 CASPubMedWeb of Science®Google Scholar 8 Honda Z., Nakamura M., Miki I., Minami M., Watanabe T., Seyama Y., Okado H., Toh H., Ito K., Miyamoto T., Shimizu T. Cloning by functional expression of platelet-activating factor receptor from guinea pig lung. Nature: 1991; 349: 342–6. 10.1038/349342a0 CASPubMedWeb of Science®Google Scholar 9 Ye RD, Prossniz ER, Zou A., Cochrane CG. Characterization of a human cDNA that encodes a functional receptor for platelet-activating factor. Biochem Biophys Res Commun 1991; 180: 105–11. 10.1016/S0006-291X(05)81261-6 CASPubMedWeb of Science®Google Scholar 10 Nakamura M., Honda Z., Izumi T., Sakanaka C., Mutoh H., Bito M., Seyama Y., Matsumoto M., Shimizu T. Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J Biol Chem 1991; 266: 20400–405. CASPubMedWeb of Science®Google Scholar 11 Kunz D., Gerard NP, Gerard C. The human leukocyte platelet-activating factor receptor. J Biol Chem 1992; 267: 9101–6. CASPubMedWeb of Science®Google Scholar 12 Seyfried CE, Schweickart VL, Godiska R., Gray PW. The human platelet-activating factor receptor (PAFR) gene contains no introns and maps to chromosome 1. Genomics 1992; 13: 832–4. 10.1016/0888-7543(92)90162-L CASPubMedWeb of Science®Google Scholar 13 Müller E., Dagenais P., Alami N., Rola-Pleszczynski M. Identification and functional characterization of platelet-activating factor receptors in human leukocyte populations using polyclonal anti-peptide antibody. Proc Natl Acad Sci USA 1993; 90: 5818–22. 10.1073/pnas.90.12.5818 CASPubMedWeb of Science®Google Scholar 14 Ouellet S., Müller E., Rola-Pleszczynski M. IFN-γ upregulates platelet-activating factor receptor gene expression in human monocytes. J Immunol 1994; 152: 5092–9. CASPubMedWeb of Science®Google Scholar 15 Thivierge M., Alami N., Müller E., De Brum-Fernandes AJ, Rola- Pleszczynski M. Transcriptional modulation of platelet-activating factor receptor gene expression by cyclic AMP. J Biol Chem 1993; 268: 17457–62. CASPubMedWeb of Science®Google Scholar 16 Saunders RN, Handley DA. Platelet-activating factor antagonists. Annu Rev Pharmacol Toxicol 1987; 27: 237–55. 10.1146/annurev.pa.27.040187.001321 CASPubMedWeb of Science®Google Scholar 17 Stremler KE, Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: oxidatively- fragmented phospholipids as substrates. J Biol Chem 1991; 266: 11095–103. CASPubMedWeb of Science®Google Scholar 18 Patel K., Zimmerman GA, Prescott SM, McIntyre TM. Novel leukocyte agonists are released by endothelial cells exposed to peroxide. J Biol Chem 1992; 267: 1568–75. Google Scholar 19 Stafforini DM, Prescott SM, Zimmerman GA, McIntyre TM. Platelet-activating factor acetylhydrolase activity in human tissues and blood cells. Lipids 1991; 26: 979–85. 10.1007/BF02536488 CASPubMedWeb of Science®Google Scholar 20 Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: purification and properties. J Biol Chem 1987; 262: 4223–30. CASPubMedWeb of Science®Google Scholar 21 Stafforini DM, Rollins EN, Prescott SM, McIntyre TM. The platelet-activating factor acetylhydrolase from human erythrocytes: purification and properties. J Biol Chem 1993; 268: 3857–65. CASPubMedWeb of Science®Google Scholar 22 Hattori M., Arai H., Inoue K. Purification and characterization of bovine brain platelet-activating factor acetylhydrolase. J Biol Chem 1993; 268: 18748–53. CASPubMedWeb of Science®Google Scholar 23 Hattori M., Adachi H., Tsujimoto M., Arai H., Inoue K. Miller- Dieker lissencephaly gene encodes a subunit of brain platelet-activating factor acetylhydrolase. Nature 1994; 370: 216–18. 10.1038/370216a0 CASPubMedWeb of Science®Google Scholar 24 Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase: association with lipoprotein particle and role in the degradation of platelet-activating factor. J Biol Chem 1987; 262: 4215–22. CASPubMedWeb of Science®Google Scholar 25 Elstad MR, Stafforini DM, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor acetylhydrolase increases during macrophage differentiation: a novel mechanism that regulates accumulation of platelet-activating factor. J Biol Chem 1989; 264: 8467–70. CASPubMedWeb of Science®Google Scholar 26 Satoh K., Imaizumi T., Kawamura Y., Yoshida H., Hiramoto M., Takamatsu S., Takamatsu M. Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2. J Clin Invest 1991; 87: 476–81. 10.1172/JCI115020 CASPubMedWeb of Science®Google Scholar 27 Tarbet B., Stafforini DM, Elstad MR, Zimmerman GA, McIntyre TM, Prescott SM. Liver cells secrete the plasma form platelet-activating factor acetylhydrolase. J Biol Chem 1991; 266: 16667–73. CASPubMedWeb of Science®Google Scholar 28 Yamada Y., Stafforini DM, Imaizumi T., Zimmerman GA, McIntyre TM, Prescott SM. Characterization of the platelet-activating factor acetylhydrolase from human plasma by heterologous expression in Xenopus laevis oocytes. Proc Natl Acad Sci USA 1995; 91: 10320–24. 10.1073/pnas.91.22.10320 PubMedWeb of Science®Google Scholar 29 Satoh K., Imaizumi T., Yoshida H., Takamatsu S. Effect of 17-b estradiol on the secretion of platelet-activating factor acetyl- hydrolase by hepG2 cells. Metabolism 1993; 42: 672–7. 10.1016/0026-0495(93)90231-C CASPubMedWeb of Science®Google Scholar 30 Satoh K., Imaizumi T., Yoshida H., Takamatsu S. High density lipoprotein inhibits the production of platelet-activating factor acetylhydrolase by HepG2 cells. J Lab Clin Med 1994; 124: 225–31. Google Scholar 31 Narahara H., Johnston JM. Effects of endotoxins and cytokines on the secretion of platelet-activating factor acetylhydrolase by human decidual macrophages. Am J Obst Gynecol 1993; 169: 531–7. 10.1016/0002-9378(93)90614-O CASPubMedWeb of Science®Google Scholar 32 Elstad MR, Stafforini DM, Stremler KE, Zimmerman GA, McIntyre TM, Prescott SM. The potential role of the PAF acetylhydrolase in human disease. In: K. Saito, D. Hanahan, eds. Platelet-activating Factor and Diseases. Tokyo: International Medical Publishers, 1989: 69–84. Google Scholar 33 Miwa M., Miyake T., Yamaoka T., Sugatanu J., Suzuki Y., Sakata S., Araki Y., Matsumoto M. Characterization of serum platelet-activating factor (PAF) acetylhydrolase: Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest 1988; 82: 1983–91. 10.1172/JCI113818 CASPubMedWeb of Science®Google Scholar 34 Satoh K., Imaizumi T., Kawamura Y., Yoshida H., Takamatsu S., Takamatsu M. Increased activity of platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension. Prostaglandins 1989; 37: 673–82. 10.1016/0090-6980(89)90104-4 CASPubMedWeb of Science®Google Scholar 35 Maki N., Magness RR, Miyaura S., Gant NF, Johnston JM. Platelet-activating factor acetylhydrolase activity in normotensive and hypertensive pregnancies. Am J Obst Gynecol 1993; 168: 50–54. 10.1016/S0002-9378(12)90883-2 CASPubMedWeb of Science®Google Scholar 36 Ostermann G., Ruhling K., Zabel-Langhennig R., Winkler L., Schlag B., Till U. Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor. Thromb Res 1987; 47: 279–85. 10.1016/0049-3848(87)90141-1 CASPubMedWeb of Science®Google Scholar 37 Ostermann G., Lang A., Holz H., Ruhling K., Winkler L., Till U. The degradation of platelet-activating factor in serum and its discrimitive value in atherosclerotic patients. Thromb Res 1988; 52: 529–40. 10.1016/0049-3848(88)90126-0 CASPubMedWeb of Science®Google Scholar 38 Satoh K., Imaizumi T., Kawamura Y., Yoshida H., Takamatsu S., Mizumo S. Activity of platelet-activating factor (PAF) acetyl- hydrolase in plasma from patients with ischemic cerebrovascular disease. Prostaglandins 1988; 35: 685–98. 10.1016/0090-6980(88)90142-6 CASPubMedWeb of Science®Google Scholar 39 Satoh K., Yoshida H., Imaizumi T., Takamatsu S., Mizuno S. Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke. Stroke 1992; 23: 1090–92. 10.1161/01.STR.23.8.1090 PubMedWeb of Science®Google Scholar 40 Pritchard PH, Chonn A., Yeung CCH. The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease). Blood 1985; 66: 1476–8. CASPubMedWeb of Science®Google Scholar 41 Hofmann B., Ruhling K., Spangeberg P., Ostermann G., Enhanced degradation of platelet-activating factor in serum from diabetic patients Haemostasis 1989; 19: 180–84. CASPubMedWeb of Science®Google Scholar 42 Meade CJ, Metcalfe S., Svvennsen R., Jamieson N., Watson C., Calne RY, Kleber G., Nield G. Serum PAF acetylhydrolase and chronic cholestasis. Lancet 1991; 338: 1016–17. 10.1016/0140-6736(91)91876-V CASPubMedWeb of Science®Google Scholar 43 Dulioust A., Hilliquin P., Mekes CJ, Benveniste J., Arnoux B. PAF-acether acetylhydrolase activity is increased in patients with rheumatic diseases. Scand J Rheumatol 1992; 21: 161–4. 10.3109/03009749209099215 CASPubMedWeb of Science®Google Scholar 44 Imaizumi T., Satoh K., Yoshida H., Kawamura Y., Hiramoto M., Koyanagi M., Takamatsu S., Takamatsu M. Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from healthy habitual cigarette smokers. Heart Vessels 1990; 5: 81–6. 10.1007/BF02058322 CASPubMedGoogle Scholar 45 Graham RM, Stephens CJ, Silvester W., Leong LLL, Strurm MJ, Taylor RR. Plasma degradation of platelet-activating factor in severely ill patients with clinical sepsis. Crit Care Med 1994; 22: 204–12. 10.1097/00003246-199402000-00009 PubMedWeb of Science®Google Scholar 46 Tetta C., Bussolino F., Modena V., Montrucchio G., Segoloni G., Pescarmona G., Camussi G. Release of platelet-activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol 1990; 91: 244–56. 10.1159/000235124 CASPubMedWeb of Science®Google Scholar 47 Caplan MS, Sun XM, Hsueh W., Hageman JR. Role of platelet-activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis. J Pediatr 1990; 116: 960–64. 10.1016/S0022-3476(05)80661-4 CASPubMedWeb of Science®Google Scholar 48 Stephens CJ, Graham RM, Yadava OP, Leong LLL, Sturm MJ, Taylor RR. Plasma platelet-activating factor degradation and serum lipids after coronary bypass surgery. Cardiovasc Res 1992; 26: 25–31. 10.1093/cvr/26.1.25 CASPubMedWeb of Science®Google Scholar 49 Kirschbaum B. Platelet-activating factor acetylhydrolase activity in the urine of patients with renal diseases. Clin Chim Acta 1991; 199: 139–46. 10.1016/0009-8981(91)90105-L CASPubMedWeb of Science®Google Scholar 50 Yoshida H., Satoh K., Imaizumi T., Takamatsu S., Hiramoto M., Shoji B., Takamatsu M. Platelet-activating factor acetyl- hydrolase activity in red blood cell stroma from patients with cerebral thrombosis. Acta Neurol Scand 1992; 86: 199–203. 10.1111/j.1600-0404.1992.tb05066.x CASPubMedWeb of Science®Google Scholar 51 Yoshida H., Satoh K., Takamatsu S. Platelet-activating factor acetylhydrolase in red blood cell membranes: does decreased activity impair erythrocyte deformability in ischemic stroke patients? Stroke 1993; 24: 14–18. 10.1161/01.STR.24.1.14 CASPubMedWeb of Science®Google Scholar 52 Zimmerman GA, Lorant DE, McIntyre TM, Prescott SM. Juxtacrine intercellular signalling: another way to do it. Am J Resp Cell Mol Biol 1993; 9: 537–77. 10.1165/ajrcmb/9.6.573 Google Scholar 53 Zimmerman GA, Elstad MR, Lorant DE, Patel KD, Topham MK, Whatley RE, McIntyre TM, Prescott SM. Platelet-activating factor: new roles in cell-cell interactions. J Lipid Mediators Cell Signaling 1994; 10: 57–9. CASWeb of Science®Google Scholar 54 Tanaka T., Minamino H., Unezaki S., Tsukatani H., Tokumura A. Formation of platelet-activating factor-like phospholipids by Fe2+/ascorbate/EDTA-induced lipid peroxidation. Biochem Biophys Acta 1993; 1166: 264–74. 10.1016/0005-2760(93)90107-K CASPubMedWeb of Science®Google Scholar 55 Caramelo C., Fernandez-Gallardo S., Marin-Cao D., Inarrea P., Santos JC, Lepez-Novaa JM, Sanchez-Crespo M. Presence of platelet-activating factor in blood from human and experimental animals. Its absence in anephritic individuals. Biochem Biophys Res Commun 1984; 120: 789–96. 10.1016/S0006-291X(84)80176-X CASPubMedWeb of Science®Google Scholar 56 Bussolino F., Porcellini MG, Varese L., Bosia A. Intravascular release of platelet-activating factor in children with sepsis. Thromb Res 1987; 48: 619–20. 10.1016/0049-3848(87)90396-3 CASPubMedWeb of Science®Google Scholar 57 Lazanas M., Demopoulus CA, Tournis S., Koussissis S., Labrakis- Lazanas K., Tsarouhas X. PAF of biological fluids in disease: IV, Levels in blood in allergic reaction induced by drugs. Arch Dermatol Res 1988; 289: 124–6. 10.1007/BF00417717 CASWeb of Science®Google Scholar 58 Grandel KE, Farr RS, Wanderer AA, Elsenstadt TC, Wasserman SI. Association of platelet-activating factor with primary cold urticaria. N Eng J Med 1985; 313: 405–9. 10.1056/NEJM198508153130702 PubMedWeb of Science®Google Scholar 59 Satoh K., Imaizumi T., Yoshids H., Hiramoto M., Takamatsu S. Increased levels of blood platelet-activating factor (PAF) and PAF-like lipids in patients with ischemic stroke. Acta Neurol Scand 1992; 85: 122–7. 10.1111/j.1600-0404.1992.tb04010.x CASPubMedWeb of Science®Google Scholar 60 Caramelo C., Fernandez-Gallardo S., Santos JC, Inarrea P., Sanchez-Crespo M., Lopez-Novoa JM, Hernando L. Increased levels of platelet-activating factor in blood from patients with cirrhosis of the liver. Eur J Clin Invest 1987; 17: 7–11. 10.1111/j.1365-2362.1987.tb01218.x PubMedWeb of Science®Google Scholar 61 Moreno P., Gijon MA, Fradera GR, Fabregat J., Rafecas A., Biondo S., Figueras J., Sanchez-Cresp M., Jaurrieta E. Changes in peripheral blood levels of platelet-activating factor after orthotopic liver transplantation. Transplant Proc 1993; 25: 2642–3. CASPubMedWeb of Science®Google Scholar 62 Imaizumi T., Satoh K., Yoshida H., Kawamura Y., Hiramoto M., Takamatsu S. Effect of cigarette smoking on the levels of platelet-activating factor-like lipid(s) in plasma lipoproteins. Atherosclerosis 1991; 87: 47–55. 10.1016/0021-9150(91)90231-Q CASPubMedWeb of Science®Google Scholar 63 Miadonna A., Tedeschi A., Arnoux B., Sala A., Zanussi C., Benveniste J. Evidence of PAF-acether metabolic pathway activation in antigen challenge of upper respiratory airways. Am Rev Respir Dis 1989; 140: 142–7. 10.1164/ajrccm/140.1.142 CASPubMedWeb of Science®Google Scholar 64 Sobhani I., Hochlaf S., Denizot Y., Vissuzaine C., Rane E., Benveniste J., Lewin MMJ, Mignon M. Raised concentration of platelet-activating factor in colonic mucosa of Crohn's disease patients. Gut 1992; 33: 1220–25. 10.1136/gut.33.9.1220 CASPubMedWeb of Science®Google Scholar 65 Ferraris L., Karmeli F., Eliakim R., Klein J., Ficchi C., Rachmilewitz D. Intestinal epithelial cells contribute to the enhanced generation of platelet-activating factor in ulcerative colitis. Gut 1993; 34: 665–8. 10.1136/gut.34.5.665 CASPubMedWeb of Science®Google Scholar 66 Noris M., Benigni A., Boccardo P., Gotti E., Benfenati E., Aiello S., Todeschini M., Remuzzi G. Urinary excretion of platelet-activating factor in patients with immune-mediated glomerulonephritis. Kidney Int 1993; 43: 426–9. 10.1038/ki.1993.62 CASPubMedWeb of Science®Google Scholar 67 Benigni A., Boccardo P., Noris M., Remuzzi G., Siegler RL. Urinary excretion of platelet-activating factor in hemolytic uraemic syndrome. Lancet 1992; 339: 835–6. 10.1016/0140-6736(92)90281-7 CASPubMedWeb of Science®Google Scholar 68 Hoffman DR, Romero R. Detection of platelet-activating factor in amniotic fluid of complicated pregnancies. Am J Obstet Gynecol 1990; 162: 525–8. 10.1016/0002-9378(90)90423-5 CASPubMedWeb of Science®Google Scholar 69 Arditi M., Manogue KR, Caplan M., Yogev R. Cerebrospinal fluid cachectin/tumor necrosis factor-α and platelet-activating factor concentrations and severity of bacterial meningitis in children. J Infect Dis 1990; 162: 139–47. 10.1093/infdis/162.1.139 CASPubMedWeb of Science®Google Scholar 70 Braquet P., Touqui L., Shen T-Y, Vargaftig BB. Perspectives in platelet-activating factor research. Pharmacol Rev 1987; 39: 97–145. CASPubMedWeb of Science®Google Scholar 71 Braquet P., Paubert-Braquet M., Koltai M., Bourgain R., Bussolino F., Hosford D. Is there a case for PAF antagonists in the treatment of ischemic states? Trends Pharmacol Sci 1989; 10: 23–30. 10.1016/0165-6147(89)90103-X CASPubMedWeb of Science®Google Scholar 72 Braquet P., Hosford D., Braquet M., Bourgain R., Bussolino F. Role of cytokines and platelet-activating factor in micro-vascular immune injury. Int Arch Allergy Appl Immunol 1989; 88: 88–100. 10.1159/000234755 PubMedWeb of Science®Google Scholar 73 Caplan MS, Hsueh W. Necrotizing enterocolitis: Role of platelet activating factor, endotoxin, and tumor necrosis factor. J Pediatr 1990; 117: S47–51. 10.1016/S0022-3476(05)81130-8 CASPubMedWeb of Science®Google Scholar 74 Furukawa M., Lee EL, Johnston JM. Platelet-activating factor- induced ischemic bowel necrosis: the effect of platelet-activating factor acetylhydrolase. Pediatr Res 1993; 34: 237–41. 10.1203/00006450-199308000-00027 CASPubMedWeb of Science®Google Scholar 75 Sun X-M, Hsueh W. Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. J Clin Invest 1988; 81: 1328–31. 10.1172/JCI113459 CASPubMedWeb of Science®Google Scholar 76 Hsueh W., Caplan MS, Sun X., Tan X., MacKendrick W., Gonzalez-Crussi F. Platelet-activating factor, tumor necrosis factor, hypoxia and necrotizing enterocolitis. Acta Paediatr Suppl 1994; 396: 11–17. 10.1111/j.1651-2227.1994.tb13234.x CASPubMedWeb of Science®Google Scholar 77 Diez FL, Nieto ML, Fernandez-Gallardo S., Gijon MA, Crespo Sanchez M. Occupancy of platelet receptors for platelet-activating factor in patients with septicemia. J Clin Invest 1989; 83: 1733–40. 10.1172/JCI114074 CASPubMedWeb of Science®Google Scholar 78 Guinot P., Braquet P. Effects of the PAF-antagonists, ginkgolides BN 52063. BN 52021, in various clinical indications. J Lipid Mediators Cell Signalling 1994; 10: 144–146. Google Scholar 79 Chang S-W, Fernyak S., Voelkel NF. Beneficial effect of a platelet-activating factor antagonist. WEB 2086, on endotoxin- induced lung injury. Am J Physiol 1990; 258: H153–8. CASPubMedWeb of Science®Google Scholar 80 Szabó C., Wu C-C, Mitchell JA, Gross SS, Thiemermann C., Vane JR. Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res 1993; 73: 991–9. 10.1161/01.RES.73.6.991 CASPubMedWeb of Science®Google Scholar 81 Nakamura M., Honda Z., Waga I., Matsumoto T., Noma M., Shimizu T. Endotoxin transduces Ca2+ signaling via platelet-activating factor receptor. FEBS Lett 1992; 314: 125–9. 10.1016/0014-5793(92)80957-I CASPubMedWeb of Science®Google Scholar 82 Waga I., Nakamura M., Honda Z., Ferby I., Toyoshima S., Ishiguro S., Shimizu T. Two distinct signal transduction pathways for the activation of guinea-pig macrophages and neutrophils by endotoxin. Biochem Biophys Res Commun 1993; 197: 465–72. 10.1006/bbrc.1993.2502 CASPubMedWeb of Science®Google Scholar 83 Miyaura S., Maki N., Byrd W., Johnston JM. The hormonal regulation of platelet-activating factor acetylhydrolase activity in plasma. Lipids 1991; 26: 1015–20. 10.1007/BF02536494 CASPubMedWeb of Science®Google Scholar 84 Tedeschi A., Palumbo G., Milazzo N., Miadonna A. Nasal neutrophilia and eosinophilia induced by challenge with platelet-activating factor. J Allergy Clin Immunol 1994; 93: 526–33. 10.1016/0091-6749(94)90363-8 PubMedWeb of Science®Google Scholar 85 Mencia-Heurta JM, Hosford D., Braquet P. Acute and long- term pulmonary effects of platelet-activating factor. Clin Exp Allergy 1989; 19: 125–42. 10.1111/j.1365-2222.1989.tb02356.x PubMedWeb of Science®Google Scholar 86 Smith LJ. The role of platelet-activating factor in asthma. Am Rev Resp Dis 1991; 143: S100–102. 10.1164/ajrccm/143.5_Pt_2.S100 CASPubMedWeb of Science®Google Scholar 87 Simon H-U, Tsao PW, Siminovitch KA, Mills GB, Blaser K. Functional platelet-activating factor receptors are expressed by monocytes and granulocytes but not by resting or activated T and B lymphocytes from normal individuals or patients with asthma. J Immunol 1994; 153: 364–77. CASPubMedWeb of Science®Google Scholar 88 Morley J., Smith D., Sanjar S., Mazzoni L. PAF and the respiratory system. In: K. Saito, DJ Hanahan, eds. Platelet-activating Factor and Diseases. Tokyo: International Medical Publishers, 1989: 187–206. Google Scholar 89 Spence DPS, Johnston SL, Calverley PMA, Dhillon P., Higgins C., Ramhamadany E., Turner S., Winning A., Winter J., Holgate ST. The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. Am J Respir Crit Care Med 1994; 149: 1142–8. 10.1164/ajrccm.149.5.8173754 CASPubMedWeb of Science®Google Scholar 90 Stoll LL, Denning GM, Kasner NA, Hunninghake GW. Platelet-activating factor may stimulate both receptor-dependent and receptor-independent increases in [Ca2+] in human airway epithelial cells. J Biol Chem 1994; 269: 4254–9. CASPubMedWeb of Science®Google Scholar 91 Blank ML, Snyder F., Byers LW, Brooks B., Murihead EE. Antihypertensive activity of an alkyl ether analog of phosphatidyl-choline. Biochem Biophys Res Commun 1979; 90: 1194–200. 10.1016/0006-291X(79)91163-X CASPubMedWeb of Science®Google Scholar 92 Stafforini DM, Carter ME, Zimmerman GA, McIntyre TM, Prescott SM. Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma. Proc Natl Acad Sci USA 1989; 86: 2393–7. 10.1073/pnas.86.7.2393 CASPubMedWeb of Science®Google Scholar 93 Dzau VJ, Gibbons GH, Morishita R., Pratt RE. New perspectives in hypertension research. Potentials of vascular biology. Hypertension 1994; 23: 1132–40. 10.1161/01.HYP.23.6.1132 CASPubMedWeb of Science®Google Scholar 94 Ross R. The pathogenesis of atherosclerosis: a perspective for 1990s. Nature 1993; 362: 801–9. 10.1038/362801a0 CASPubMedWeb of Science®Google Scholar 95 Steinbrecher UP, Parthasathy S., Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipids peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984; 81: 3883–7. 10.1073/pnas.81.12.3883 CASPubMedWeb of Science®Google Scholar 96 Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein. Trans Assoc Amer Phys 1992; 105: 44–63. CASPubMedWeb of Science®Google Scholar 97 Ambrosio G., Oriente A., Napoli C., Palumbo G., Chiariello P., Marone G., Condorelli M., Chiariello M., Triggani M. Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. J Clin Invest 1994; 93: 2408–16. 10.1172/JCI117248 CASPubMedWeb of Science®Google Scholar 98 Evangelou AM. Platelet-activating factor (PAF): implications for coronary heart and vascular diseases. Prostaglandins Leukot Essent Fatty Acids 1994; 50: 1–28. 10.1016/0952-3278(94)90101-5 CASPubMedWeb of Science®Google Scholar 99 Holland MR, McIntyre TM, Zimmerman GA, Prescott SM. Cardiovascular effects of platelet-activating factor. Trends Cardiovasc Med 1991; 1: 117–21. 10.1016/1050-1738(91)90005-Y CASPubMedWeb of Science®Google Scholar 100 Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. Platelet-activating factor and atherosclerotic cardiovascular disease. In: RB Francis, ed. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. New York: Dekker, 1992: 307–29. Google Scholar 101 Prescott SM, Patel KD, Smiley PL, Stafforini DM, Lorant DE, Zimmerman GA, McIntyre TM. Potential roles for oxidized phospholipids in inflammation and atherogenesis. Atherosclerosis Reviews 1993; 25: 59–68. CASGoogle Scholar 102 Kato K., Clark GD, Bazan NG, Zorumski CF. Platelet-activating factor as a potential retrograde messenger in CA1 hippocampal long-term potentiation. Nature 1994; 367: 175–9. 10.1038/367175a0 CASPubMedWeb of Science®Google Scholar 103 Sugatani J., Fujimura T., Mizuno Y., Sameshima Y., Saitoh K. The role of platelet-activating factor (PAF) in the pathogenesis of gastric ulcers. Prostaglandins Leukot Essnt Fatty Acids 1991; 44: 135–47. 10.1016/0952-3278(91)90048-A CASPubMedWeb of Science®Google Scholar 104 Sanchez-Crespo M., Inarrea P., Alvarez V., Alonso F., Egido J., Hernando L. Presence in normal human urine of a hypotensive and platelet-activating phospholipid. Am J Physiol 1983; 244: F706–11. CASPubMedWeb of Science®Google Scholar 105 Shukla SD, Paul A., Klachko DM. Hypersensitivity of diabetic human platelets to platelet-activating factor. Thromb Res 1992; 66: 239–46. 10.1016/0049-3848(92)90194-F CASPubMedWeb of Science®Google Scholar 106 Billah MM, Johnston JM. Identification of phospholipid- activating factor (1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human amniotic fluid and urine. Biochem Biophys Res Commun 1983; 113: 51–8. 10.1016/0006-291X(83)90430-8 CASPubMedWeb of Science®Google Scholar 107 Maki N., Hoffman D., Johnston JM. Platelet-activating factor acetylhydrolase activity during pregnancy and lactation. Proc Natl Acad Sci USA 1988; 85: 728–32. 10.1073/pnas.85.3.728 CASPubMedWeb of Science®Google Scholar 108 Kobayashi T., Sagawa N., Ihara Y., Kitagawa K., Yano J., Mori T. Platelet-activating factor-acetylhydrolase activity in maternal and umbilical venous plasma obtained from normotensive and hypertensive pregnancies. Obstet Gynecol 1994; 84: 360–64. CASPubMedWeb of Science®Google Scholar 109 Yokode M., Kita T., Arai H., Kawai C., Narumiya S., Fujiwara M. Cholesteryl ester accumulation in macrophages incubated with low density lipoprotein pretreated with cigarette smoke extract. Proc Natl Acad Sci USA 1988; 85: 2344–8. 10.1073/pnas.85.7.2344 CASPubMedWeb of Science®Google Scholar 110 Miyaura S., Egucgi H., Johnston JM. Effect of cigarette smoke extract on the metabolism of the proinflammatory autacoid, platelet-activating factor. Circ Res 1992; 70: 341–7. 10.1161/01.RES.70.2.341 CASPubMedWeb of Science®Google Scholar 111 Narahara H., Johnston JM. Smoking and preterm labor: effect of cigarette smoke extract on the secretion of platelet-activating factor acetylhydrolase by human decidual macrophages. Am J Obst Gynecol 1993; 169: 1321–6. 10.1016/0002-9378(93)90300-8 CASPubMedWeb of Science®Google Scholar 112 Honda Z., Takano T., Gotoh Y., Nishida E., Ito K., Shimizu T. Transfected platelet-activating factor receptor activates mitogen-activated protein (MAP) kinase and MAP kinase kinase in Chinese hamster ovary cells. J Biol Chem 1994; 269: 2307–15. 10.1016/S0021-9258(17)42169-7 CASPubMedWeb of Science®Google Scholar Citing Literature Volume238, Issue1July 1995Pages 5-20 ReferencesRelatedInformation
Referência(s)